NAD Treatment Center Contributes to Potential a Treatment for Alzheimer's by Participating in Young Blood Institute Study

2018-08-03 12:00:00

Press Release - updated: Aug 3, 2018 09:00 PDT

SAN DIEGO, August 3, 2018 - NAD Treatment Center, an outpatient facility and leader in the intravenous NAD+ industry, located in San Diego, California, contributes its resources to find an effective therapy for Alzheimer’s disease, a neurodegenerative condition that affects almost 44 million people worldwide. The clinic specializes in revolutionary intravenous vitamin therapies for chronic conditions, addiction recovery and anti-aging, such as Nicotinamide Adenine Dinucleotide (NAD+), phosphatidylcholine, glutathione, high dose Vitamin C, and most recently, plasmapheresis.

As we age, our immune system declines and weakens the body’s defenses against age-related diseases. Plasmapheresis, also known as Therapeutic Plasma Exchange (TPE), was first introduced in 1951 and was recently approved by the FDA in 1996. TPE supports and restores the immune system for patients with autoimmune disorders, and recently has gained attention for its potential application in age-related diseases. During the treatment, a specialized machine replaces the old blood plasma with new purified plasma components, such as immunoglobulins and albumin, which act as powerful agents to remove pathogenic substances from the bloodstream. TPE helps rejuvenate the immune system and strengths the body’s ability to regulate inflammation and by removing inhibitory factors in aged blood.

The Young Blood Institute, a 501(c)(3) nonprofit corporation located in Stanford, California, founded by Mark Urdahl, provides world-class principal investigators, medical staff, apheresis equipment, and scientific biomarkers to implement TPE therapy under an Internal Review Board approved study in clinics across the country.

This trial will introduce new advancements in the early detection of immune deficiencies, as well as measure the restoration of key immune system factors by comparing the aged blood to the blood from autoimmune patients' that have previously undergone plasma exchange, and we will also study the potential to replicate prior study success in treating Alzheimer's with TPE by utilizing a minimally invasive blood test for Alzheimer's disease.

Mark Urdahl

Young Blood Institute

“This trial will introduce new advancements in the early detection of immune deficiencies, as well as measure the restoration of key immune system factors by comparing the aged blood to the blood from autoimmune patients’ that have previously undergone plasma exchange,” according to Mr. Urdahl, “and we will also study the potential to replicate prior study success in treating Alzheimer’s with TPE by utilizing a minimally invasive blood test for Alzheimer’s disease.”

Over the next couple of years, the Young Blood Institute will gather 1,000 participants of at least 50 years of age with two or more age-related conditions. The objective is to evaluate the effect of TPE as a modality to prevent age-associated disorders through an extensive set of scientific biomarkers that serve as a method for early detection in the decline of immune and neurological factors.

For more information on plasmapheresis, or to inquire about enrolling into the Young Blood Institute’s study, please contact [email protected], or call 844-623-7587.

Plasmapheresis, also known as Therapeutic Plasma Exchange therapy, intravenously removes a patient’s plasma, the fluid component of the blood, while simultaneously replacing it with donor plasma or purified plasma components such as immunoglobulins and albumin. The added components often found in younger blood provide antioxidant support and helps restore our body’s immune system. University scientists have also observed the rejuvenative effects of old-for-young blood exchange in animal models that cellular behavior and new growth of cells in muscle, organ, and brain tissue. Recent human studies have shown promising interim results using plasmapheresis to improve and restore cognitive functions in patients with Alzheimer’s disorder.

NAD+ (Nicotinamide Adenine Dinucleotide) is a simple metabolic coenzyme of Niacin, a B Vitamin that is involved in energy production for every mitochondria within our bodies. Research has shown that NAD+ levels decline with age, and populations afflicted with addiction, alcoholism, stress and depression, also have an NAD+ deficiency. The treatment replenishes the supply of neurotransmitters and promotes healthy brain function. It is based completely on nutrients that are found naturally within a healthy body.

The announcement of the NAD Treatment Center participation in the Young Blood Institutes study follows their announcement of co-hosting the Third Annual NAD Summit.

About NAD Treatment Center

NAD Treatment Center is located at 4080 Centre Street, Suite #207 San Diego, California. It is an outpatient facility and all patients are supervised by medical professionals throughout their treatment. The clinic is on the cutting edge of innovating intravenous NAD⁺ by combining the latest technology and alternative therapies to tailor a treatment protocol program for each individual. Our treatment program is unique because we minimize the amount of medication people have to take and restore their brain on a cellular level. For additional information, call (844) 623-7587 or visit us online at NADTreatmentCenter.com.

Source: NAD Treatment Center